Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women

HIV Clinical Trials

Volumn 13, Issue 6, 2012, Pages 308-323

  Hermes, A ^a   Squires, K ^b   Fredrick, L ^a   Martinez, M ^a   Pasley, M ^a   Trinh, R ^a   Norton, M ^a  

^a ABBOTT LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

age groups; body mass index; efficacy; HIV 1; lopinavir ritonavir; men; safety

Indexed keywords

LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ABDOMINAL PAIN; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INTENTION TO TREAT ANALYSIS; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE FACTORS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; RITONAVIR; RNA, VIRAL;

EID: 84870616991     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1306-308     Document Type: Article

References (37)

1. UNAIDS. UNAIDS annual report 2009: uniting the world against AIDS. Joint United Nations Programme on HIV/AIDS (UNAIDS). June 2010. http://www.unaids. org/en/media/unaids/contentassets/dataimport/pub/report/2010/ 2009-annual-report-en.pdf. Accessed October 1, 2012
2. World Health Organization. Global Health Observatory HIV/AIDS Data, 2009. Geneva, Switzerland: World Health Organization; 2011
3. Centers for Disease Control and Prevention. HIV among women, August 2011. http://www.cdc.gov/hiv/topics/women/pdf/women.pdf. Accessed June 15, 2012
4. Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: results from the Steps Study. AIDS Behav. 2011;15(6):1161-1170
5. Cavaleri M, Kalogerogiannis K, McKay M, et al. Barriers to HIV care: an exploration of the complexities that infl uence engagement in and utilization of treatment. Soc Work Health Care. 2010;49(10):934-945
6. Duff P, Kipp W, Wild TC, Rubaale T, Okech-Ojony J. Barriers to accessing highly active antiretroviral therapy by HIVpositive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc. 2010;13:37
7. Moneyham L, McLeod J, Boehme A, et al. Perceived barriers to HIV care among HIV-infected women in the Deep South. J Assoc Nurses AIDS Care. 2010;21(6):467-477
8. Kempf MC, McLeod J, Boehme AK, et al. A qualitative study of the barriers and facilitators to retention-in-care among HIV-positive women in the rural southeastern United States: implications for targeted interventions. AIDS Patient Care STDS. 2010;24(8):515-520
9. Stevens PE, Keigher SM. Systemic barriers to health care access for U.S. women with HIV: the role of cost and insurance. Int J Health Serv. 2009;39(2):225-243
10. Saint-Jean G, Metsch L, Gomez-Marin O, et al. Use of HIV primary care by HIV-positive Haitian immigrants in Miami, Florida. AIDS Care. 2011;23(4):486-493
11. Sarnquist CC, Soni S, Hwang H, Topol BB, Mutima S, Maldonado YA. Rural HIV-infected women's access to medical care: ongoing needs in California. AIDS Care. 2011;23(7):792-796
12. Soon G, Min M, Struble K, et al. Meta-analysis of efficacy outcomes for treatment-naïve and experienced HIV-infected women in randomized controlled clinical trials (RCTs) (2000-2008). Presented at: 50th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010; Boston, MA. Abstract H-1812
13. European AIDS Clinical Society. Guidelines for treatment of HIV-infected adults in Europe. http://www. europeanaidsclinicalsociety.org/index.php ?option=com-content&view=article&id=59&Itemid=41. Updated October 2011 (Version 6.0). Accessed June 25, 2012
14. Bucher HC, Wolbers M, Porter K. 2010 guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel. JAMA. 2010;304(17):1897
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 25, 2012
16. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Recommendations for a public health approach, 2010 version.http://whqlibdoc.who.int/publications/2010/ 9789241599818-eng.pdf. Accessed October 1, 2012
17. McIntyre J, Hughes M, Mellors J, et al. Effi cacy of ART with NVP+TDF/FTC vs LPV/r+TDF/FTC among antiretroviral-naïve women in Africa: OCTANE trial 2/ACTG A5208. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, CA. Abstract 153LB
18. Flexner C, Tierney C, Gross R, et al. Comparison of oncedaily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010;50(7):1041-1052
19. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIVpositive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189(2):265-272 (Pubitemid 38147251)
20. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir- based regimen is noninferior to twicedaily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defi c Syndr. 2009;50(5):474-481
21. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A oncedaily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defi c Syndr. 2006;43(2):153-160 (Pubitemid 44454808)
22. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15(1):F1-9 (Pubitemid 32055772)
23. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfi navir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26):2039-2046 (Pubitemid 34680595)
24. Reynes J, Lawal A, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral effi cacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatmentnaïve HIV-1 infected subjects. In: Program and abstracts of the XVIII International AIDS Conference; 2010; Vienna, Austria. Abstract MOAB0101
25. Zajdenverg R, Podsadecki TJ, Badal-Faesen S, et al. Similar safety and effi cacy of once-and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. J Acquir Immune Defic Syndr. 2010;54(2):143-151
26. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106 (Pubitemid 351679596)
27. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. National Institute of Allergy and Infectious Diseases, Division of AIDS Regulatory Support Center Web site. http://rsc.tech-res. com/safetyandpharmacovigilance/gradingtables.aspx. Accessed May 22, 2012
28. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867-875
29. Tenofovir disoproxil fumarate prescribing information. Gilead Sciences, Inc. Web site. http://www.viread. com/en/full-prescribing-info.aspx. Accessed May 15, 2012
30. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004;5(2):115-124
31. Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7(8): 549-557 (Pubitemid 44742356)
32. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167(7):684-691 (Pubitemid 46598461)
33. Delgado-Aros S, Locke GR 3rd, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol. 2004;99(9):1801-1806 (Pubitemid 39237512)
34. Talley NJ, Quan C, Jones MP, Horowitz M. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil. 2004;16(4):413-419 (Pubitemid 39140636)
35. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883-889
36. Hodder S, Jayaweera D, Mrus JM, Ryan R, Witek J. Efficacy and safety outcomes among treatmentexperienced women and men treated with etravirine in GRACE (Gender, Race and Clinical Experience) [published online ahead of print April 2, 2012]. AIDS Res Hum Retroviruses. 2012;28(6):544-551
37. Squires KE, Johnson M, Yang R, et al. Comparative gender analysis of the effi cacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011;66:363-370.